恒瑞医药(600276.SH)：SHR-1139注射液临床试验获批 目前国内外尚无同类药物获批上市

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection, a self-developed therapeutic biological product, with no similar drugs approved in the market to date [1] Group 1: Company Developments - The subsidiary Guangdong Heng Rui Medicine Co., Ltd. has been authorized to conduct clinical trials for SHR-1139 injection [1] - The total research and development investment for the SHR-1139 injection project has reached approximately 100.13 million yuan [1] Group 2: Market Context - Currently, there are no similar drugs approved for market use, indicating a potential unique position for SHR-1139 injection in the therapeutic landscape [1]